Detalles de la búsqueda
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495881
3.
Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies.
Rheumatology (Oxford)
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754125
4.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696588
5.
Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE.
Rheumatology (Oxford)
; 62(2): 617-628, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789257
6.
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 395(10222): 427-440, 2020 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035552
7.
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 79(5): 595-604, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253184
8.
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Clin Gastroenterol Hepatol
; 14(12): 1753-1762, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27464588
9.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
RMD Open
; 10(1)2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38388171
10.
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Arthritis Rheumatol
; 74(12): 1959-1970, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829656
11.
Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.
Clin Pharmacokinet
; 56(12): 1513-1523, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28353055
12.
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.
Inflamm Bowel Dis
; 23(7): 1047-1056, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28410341
13.
Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.
Curr Med Res Opin
; 32(12): 1937-1941, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27494777
14.
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Inflamm Bowel Dis
; 22(8): 1870-80, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27400222
Resultados
1 -
14
de 14
1
Próxima >
>>